Cell Culture / Recovery & Purification
Leverage Partnership, Technical Development and Manufacture to Deliver Next Generation High Titer Biologics Production
Biogen has two 15K facilities in Research Triangle Park, North Carolina and Hillerod, Denmark, and utilizes both for our manufacturing partnerships with other companies. Within this manufacturing relationship, we have also formed a strong and collaborative technical foundation. Projects have now been completed which go beyond Biogen’s tech transfer and manufacturing capabilities by leveraging our platform CHO process media within the partnership to deliver improved protein production. Within our partnered manufacturing molecules, several molecules have high material demand and relatively low titer output requiring high volume and frequent manufacturing; this low output might also require partners to engage more than one CMO and complicate the technology transfer and supply chain. Biogen has thus invested process development resources in upstream, downstream and analytical development, all working together to develop high titer processes in numerous programs. Across multiple CHO cell lines used by partners, the Biogen platform has shown the ability to successfully triple the titer and maintain comparable product quality. The current collaboration not only leverages the strength of the manufacturing partnership, but also facilitates an exchange of expertise from technical teams. This broad technical engagement facilitates technology transfer, enhances manufacturing support, and opens more capacity in the manufacturing facility for the other programs in need with high titer options.